Dicerna, a wholly owned subsidiary of Novo Nordisk, is focused on driving innovation in RNAi (ribonucleic acid interference) to selectively target and silence genes that cause or contribute to disease
Dicerna, a wholly owned subsidiary of Novo Nordisk, is focused on driving innovation in RNAi (ribonucleic acid interference) to selectively target and silence genes that cause or contribute to disease. Using proprietary GalXC™ and GalXC-Plus™ RNAi technologies, they discover and develop innovative RNAi-based therapies for rare and prevalent diseases.